{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:53:35Z","timestamp":1790621615531,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["23K07237"],"award-info":[{"award-number":["23K07237"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["24K10942"],"award-info":[{"award-number":["24K10942"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["24K11011"],"award-info":[{"award-number":["24K11011"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["5\\u20135"],"award-info":[{"award-number":["5\\u20135"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.braindev.2025.104457","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:27:00Z","timestamp":1759296420000},"page":"104457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Development and future prospects of exon-skipping therapy for Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"47","author":[{"given":"Yasuhiro","family":"Takeshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2025.104457_bb0005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.braindev.2025.104457_bb0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nmd.2010.09.006","article-title":"Duchenne muscular dystrophy: survival by cardio-respiratory interventions","volume":"21","author":"Ishikawa","year":"2011","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2025.104457_bb0015","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/14740338.2024.2394578","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety review","volume":"23","author":"Czifrus","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.braindev.2025.104457_bb0020","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.braindev.2025.104457_bb0025","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41573-023-00775-6","article-title":"Therapeutic approaches for Duchenne muscular dystrophy","volume":"22","author":"Roberts","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.braindev.2025.104457_bb0030","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/ng0493-283","article-title":"The structural and functional diversity of dystrophin","volume":"3","author":"Ahn","year":"1993","journal-title":"Nat Genet"},{"key":"10.1016\/j.braindev.2025.104457_bb0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/jhg.2010.49","article-title":"Mutation spectrum of the dystrophin gene in 442 Duchenne\/Becker muscular dystrophy cases from one Japanese referral center","volume":"55","author":"Takeshima","year":"2010","journal-title":"J Hum Genet"},{"key":"10.1016\/j.braindev.2025.104457_bb0040","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"key":"10.1016\/j.braindev.2025.104457_bb0045","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3390\/biomedicines11030722","article-title":"Nonsense-mediated mRNA decay factor functions in human health and disease","volume":"11","author":"Sun","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.braindev.2025.104457_bb0050","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1261\/rna.876308","article-title":"Splicing regulation: from a parts list of regulatory elements to an integrated splicing code","volume":"14","author":"Wang","year":"2008","journal-title":"RNA"},{"key":"10.1016\/j.braindev.2025.104457_bb0055","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3390\/ijms26052270","article-title":"Expansion of splice-switching therapy with antisense oligonucleotides","volume":"26","author":"Takeshima","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.braindev.2025.104457_bb0060","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1073\/pnas.74.8.3171","article-title":"Spliced segments at the 5\u2032 terminus of adenovirus 2 late mRNA","volume":"74","author":"Berget","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.braindev.2025.104457_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0092-8674(77)90180-5","article-title":"An amazing sequence arrangement at the 5\u2032 ends of adenovirus 2 messenger RNA","volume":"12","author":"Chow","year":"1977","journal-title":"Cell"},{"key":"10.1016\/j.braindev.2025.104457_bb0070","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1073\/pnas.1919416116","article-title":"Finding the tail end: the discovery of RNA splicing","volume":"117","author":"Suran","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.braindev.2025.104457_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1001016","article-title":"Genome-wide association between branch point properties and alternative splicing","volume":"6","author":"Corvelo","year":"2010","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.braindev.2025.104457_bb0080","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1101\/gad.7.3.407","article-title":"The role of exon sequences in splice site selection","volume":"7","author":"Watakabe","year":"1993","journal-title":"Genes Dev"},{"key":"10.1016\/j.braindev.2025.104457_bb0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00210743","article-title":"The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences","volume":"90","author":"Krawczak","year":"1992","journal-title":"Hum Genet"},{"key":"10.1016\/j.braindev.2025.104457_bb0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/bfgp\/elr020","article-title":"RNA splicing: disease and therapy","volume":"10","author":"Douglas","year":"2011","journal-title":"Brief Funct Genomics"},{"key":"10.1016\/j.braindev.2025.104457_bb0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13353-018-0444-7","article-title":"Splicing mutations in human genetic disorders: examples, detection, and confirmation","volume":"59","author":"Anna","year":"2018","journal-title":"J Appl Genet"},{"key":"10.1016\/j.braindev.2025.104457_bb0100","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1172\/JCI115244","article-title":"Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy Kobe","volume":"87","author":"Matsuo","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.braindev.2025.104457_bb0105","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI117693","article-title":"Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe","volume":"95","author":"Takeshima","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.braindev.2025.104457_bb0110","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1006\/bbrc.1996.1375","article-title":"Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence","volume":"226","author":"Pramono","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.braindev.2025.104457_bb0115","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/ijms26031303","article-title":"30 years since the proposal of exon skipping therapy for Duchenne muscular dystrophy and the future of pseudoexon skipping","volume":"26","author":"Matsuo","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.braindev.2025.104457_bb0120","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0387-7604(01)00326-6","article-title":"Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient","volume":"23","author":"Takeshima","year":"2001","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2025.104457_bb0125","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/hmg\/10.15.1547","article-title":"Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells","volume":"10","author":"van Deutekom","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2025.104457_bb0130","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/hmg\/ddg100","article-title":"Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients","volume":"12","author":"Aartsma-Rus","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2025.104457_bb0135","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1203\/01.pdr.0000215047.51278.7c","article-title":"Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy","volume":"59","author":"Takeshima","year":"2006","journal-title":"Pediatr Res"},{"key":"10.1016\/j.braindev.2025.104457_bb0140","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1056\/NEJMoa073108","article-title":"Local dystrophin restoration with antisense oligonucleotide PRO051","volume":"357","author":"van Deutekom","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2025.104457_bb0145","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum Mutat"},{"key":"10.1016\/j.braindev.2025.104457_bb0150","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3390\/jpm10040241","article-title":"Genotype-phenotype correlations in Duchenne and Becker muscular dystrophy patients from the Canadian neuromuscular disease registry","volume":"10","author":"Lim","year":"2020","journal-title":"J Pers Med"},{"key":"10.1016\/j.braindev.2025.104457_bb0155","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.omtn.2018.09.017","article-title":"NS-065\/NCNP-01: an antisense oligonucleotide for potential treatment of exon 53 skipping in Duchenne muscular dystrophy","volume":"13","author":"Watanabe","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.braindev.2025.104457_bb0160","doi-asserted-by":"crossref","first-page":"eaan0713","DOI":"10.1126\/scitranslmed.aan0713","article-title":"Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy","volume":"10","author":"Komaki","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.braindev.2025.104457_bb0165","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/acn3.51235","article-title":"Viltolarsen in Japanese Duchenne muscular dystrophy patients: a phase 1\/2 study","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.braindev.2025.104457_bb0170","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.braindev.2025.104457_bb0175","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JND-221656","article-title":"Efficacy and safety of viltolarsen in boys with Duchenne muscular dystrophy: results from the phase 2, open-label, 4-year extension study","volume":"10","author":"Clemens","year":"2023","journal-title":"J Neuromuscul Dis."},{"key":"10.1016\/j.braindev.2025.104457_bb0180","doi-asserted-by":"crossref","first-page":"23488","DOI":"10.1038\/s41598-024-70783-y","article-title":"Safety and efficacy of viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy","volume":"14","author":"Harper","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.braindev.2025.104457_bb0185","author":"News Release from Nippon Shinyaku Co"},{"key":"10.1016\/j.braindev.2025.104457_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.braindev.2024.10.005","article-title":"Safety and efficacy of viltolarsen treatment in patients with Duchenne muscular dystrophy: a retrospective study with 3-year follow-up","volume":"47","author":"Funato","year":"2025","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2025.104457_bb0195","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13023-017-0703-4","article-title":"Comprehensive analysis for genetic diagnosis of Dystrophinopathies in Japan","volume":"12","author":"Okubo","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.braindev.2025.104457_bb0200","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.braindev.2025.104457_bb0205","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3390\/genes15111489","article-title":"An updated analysis of exon-skipping applicability for Duchenne muscular dystrophy using the UMD-DMD database","volume":"15","author":"Leckie","year":"2024","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.braindev.2025.104457_bb0210","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa040933","article-title":"Myostatin mutation associated with gross muscle hypertrophy in a child","volume":"350","author":"Schuelke","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2025.104457_bb0215","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.3390\/ijms23095016","article-title":"An antisense oligonucleotide against a splicing enhancer sequence within exon 1 of the MSTN gene inhibits pre-mRNA maturation to act as a novel myostatin inhibitor","volume":"23","author":"Maeta","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.braindev.2025.104457_bb0220","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.3390\/ijms25116113","article-title":"Targeted antisense oligonucleotide-mediated skipping of murine Postn exon 17 partially addresses fibrosis in D2.mdx mice","volume":"25","author":"Trundle","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.braindev.2025.104457_bb0225","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.braindev.2025.104457_bb0230","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1089\/nat.2023.0027","article-title":"From failure to meet the clinical endpoint to U.S. Food and Drug Administration approval: 15th antisense oligonucleotide therapy approved Qalsody (Tofersen) for treatment of SOD1 mutated amyotrophic lateral sclerosis","volume":"33","author":"van Roon-Mom","year":"2023","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.braindev.2025.104457_bb0235","doi-asserted-by":"crossref","first-page":"11939","DOI":"10.3390\/ijms241511939","article-title":"Spinal muscular atrophy: the past, present, and future of diagnosis and treatment","volume":"24","author":"Nishio","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.braindev.2025.104457_bb0240","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2025.104457_bb0245","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","article-title":"A framework for individualized splice-switching oligonucleotide therapy","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.braindev.2025.104457_bb0250","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b\/2 trial","volume":"28","author":"Russell","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.braindev.2025.104457_bb0255","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/genes15070821","article-title":"Preparing for patient-customized N-of-1 antisense oligonucleotide therapy to treat rare diseases","volume":"15","author":"Wilton-Clark","year":"2024","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.braindev.2025.104457_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.crtox.2024.100182","article-title":"Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne muscular dystrophy: from FDA-approved drugs to peptide-conjugated ASO","volume":"7","author":"Sabrina Haque","year":"2024","journal-title":"Curr Res Toxicol"},{"key":"10.1016\/j.braindev.2025.104457_bb0265","doi-asserted-by":"crossref","first-page":"16456","DOI":"10.1073\/pnas.1910456117","article-title":"Premature termination codons in the DMD gene cause reduced local mRNA synthesis","volume":"117","author":"Garcia-Rodriguez","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.braindev.2025.104457_bb0270","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/embor.2010.208","article-title":"miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy","volume":"12","author":"Cacchiarelli","year":"2011","journal-title":"EMBO Rep"},{"key":"10.1016\/j.braindev.2025.104457_bb0275","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0086","article-title":"Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA","volume":"12","author":"Iff","year":"2023","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.braindev.2025.104457_bb0280","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.7326\/M23-1073","article-title":"The regulatory repercussions of approving muscular dystrophy medications on the basis of limited evidence","volume":"176","author":"Bendicksen","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.braindev.2025.104457_bb0285","unstructured":"ClinicalTrials.gov. Study to assess the efficacy and safety of viltolarsen in ambulant boys With DMD (RACER53). 2024 https:\/\/clinicaltrials.gov\/study\/NCT04060199?cond=Duchenne%20Muscular%20Dystrophy&term=NS&rank=8 [cited 2025 Aug 28]."},{"key":"10.1016\/j.braindev.2025.104457_bb0290","author":"UMIN-CTR"},{"key":"10.1016\/j.braindev.2025.104457_bb0295","author":"Prescribing Information"},{"key":"10.1016\/j.braindev.2025.104457_bb0300","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/jamaneurol.2015.3537","article-title":"Identifying non-Duchenne muscular dystrophy-positive and false negative results in prior Duchenne muscular dystrophy newborn screening programs: a review","volume":"73","author":"Gatheridge","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.braindev.2025.104457_bb0305","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/ijns5030027","article-title":"Duchenne muscular dystrophy newborn screening: evaluation of a new GSP\u00ae neonatal creatine kinase-MM kit in a US and Danish population","volume":"5","author":"Timonen","year":"2019","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.braindev.2025.104457_bb0310","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/acn3.51829","article-title":"Newborn screening for Duchenne muscular dystrophy: a two-year pilot study","volume":"10","author":"Tavakoli","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.braindev.2025.104457_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112968","article-title":"Therapeutic approaches to preserve the musculature in Duchenne muscular dystrophy: the importance of the secondary therapies","volume":"410","author":"Angelini","year":"2022","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.braindev.2025.104457_bb0320","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.3390\/jcm10235540","article-title":"Combination therapy with nusinersen and onasemnogene abeparvovec-xioi in spinal muscular atrophy type I","volume":"10","author":"Mirea","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.braindev.2025.104457_bb0325","first-page":"191","article-title":"Update on therapeutic drug research for Duchenne muscular dystrophy","volume":"55","author":"Takeshima","year":"2023","journal-title":"No To Hattatsu (Tokyo)"},{"key":"10.1016\/j.braindev.2025.104457_bb0330","first-page":"495","article-title":"Diagnosis and treatment of Duchenne muscular dystrophy","volume":"21","author":"Nishiyama","year":"2004","journal-title":"Shinkei Chiryo Gaku (Tokyo)"},{"key":"10.1016\/j.braindev.2025.104457_bb0335","unstructured":"ClinicalTrial.gov. https:\/\/clinicaltrials.gov\/ [cited 2025 Aug 28] 2025."},{"key":"10.1016\/j.braindev.2025.104457_bb0340","article-title":"Antisense RNA therapies for muscular dystrophies","volume":"27","author":"Arechavala-Gomeza","year":"2025","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.braindev.2025.104457_bb0345","author":"Nippon Shinyaku Co. L"},{"key":"10.1016\/j.braindev.2025.104457_bb0350","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.ymthe.2025.04.038","article-title":"Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases","volume":"33","author":"Torres-Masjoan","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.braindev.2025.104457_bb0355","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3390\/jcm10040820","article-title":"Innovative therapeutic approaches for Duchenne muscular dystrophy","volume":"10","author":"Fortunato","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.braindev.2025.104457_bb0360","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3390\/pharmaceutics15030778","article-title":"Recent trends in antisense therapies for Duchenne muscular dystrophy","volume":"15","author":"Wilton-Clark","year":"2023","journal-title":"Pharmaceutics"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760425001391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760425001391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:06:56Z","timestamp":1778540816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760425001391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0387760425001391"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2025.104457","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and future prospects of exon-skipping therapy for Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2025.104457","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Society of Child Neurology. Elsevier B.V. CC BY 4.0","name":"copyright","label":"Copyright"}],"article-number":"104457"}}